RxDoctor Payments Data

Sabeena Arora

Cardiovascular Disease · Hartford, CTNPI 1316145840

Payments from drug & device makers

$7,750in general payments, 2019–2025

Across 41 payments — averaging $189.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$6K
  • Bridgebio Pharma, Inc.$644
  • Pfizer$589
  • Abbott$152
  • Abiomed$132
  • AstraZeneca$102
  • plus $240 from 8 others

What the payments were for

  • Consulting fees$4,45557%
  • Travel & lodging$2,18728%
  • Food & beverage$1,07814%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,750 in reported general payments places this provider in the 75th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$32,805
Medicare patients
120
Services billed
315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis537$16,534,408
WainuaEplontersen Sodium11$474,815
JardianceEmpagliflozin284$427,339
EntrestoSacubitril/Valsartan30$50,172
EliquisApixaban36$47,026
FarxigaDapagliflozin Propanediol35$27,965
Torsemide217$6,099
Eplerenone52$5,264
Midodrine Hcl74$4,373
Spironolactone234$2,608
Amiodarone Hcl21$1,312
Metoprolol Succinate57$593
Carvedilol37$378
Digoxin20$351
Fludrocortisone Acetate11$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$589$16,581,433573 claims
AstraZenecaWainua, Farxiga$102$502,77946 claims
NovartisEntresto$20$50,17230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →